Detalhe da pesquisa
1.
Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage.
Am J Hum Genet
; 101(2): 255-266, 2017 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28777932
2.
Quinazolinone derivatives as inhibitors of homologous recombinase RAD51.
Bioorg Med Chem Lett
; 27(14): 3096-3100, 2017 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28545975
3.
Current challenges in metastasis research and future innovation for clinical translation.
Clin Exp Metastasis
; 39(2): 263-277, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35072851
4.
Correction to 'Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer'.
NAR Cancer
; 3(3): zcab041, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570837
5.
Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer.
NAR Cancer
; 3(2): zcab022, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34316709
6.
Circulating Tumor Cells in Metastatic Breast Cancer: From Genome Instability to Metastasis.
Front Mol Biosci
; 7: 134, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32766277
7.
Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen.
Cancers (Basel)
; 12(5)2020 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365878
8.
Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore.
Neuro Oncol
; 22(2): 216-228, 2020 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504812
9.
EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.
Mol Oncol
; 13(4): 725-737, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478887
10.
Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
JCI Insight
; 52019 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30830863
11.
Breast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling.
Front Immunol
; 9: 871, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29867925
12.
Defects in recombination activity caused by somatic and germline mutations in the multimerization/BRCA2 binding region of human RAD51 protein.
DNA Repair (Amst)
; 60: 64-76, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29100040
13.
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.
Oncotarget
; 7(37): 60087-60100, 2016 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27507046
14.
Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51.
Cancer Treat Rev
; 41(1): 35-45, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467108
15.
Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Mol Cancer Ther
; 14(10): 2321-31, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26294743
16.
Optimized exosome isolation protocol for cell culture supernatant and human plasma.
J Extracell Vesicles
; 4: 27031, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26194179
17.
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
PLoS One
; 10(5): e0125232, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25969993
18.
Rad51 supports triple negative breast cancer metastasis.
Oncotarget
; 5(10): 3261-72, 2014 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24811120
19.
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer.
Oncotarget
; 5(10): 3145-58, 2014 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24762669
20.
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
J Nucl Med
; 54(6): 913-21, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23564760